PTPRC and neoplasm: Meanwhile, the number of TILs was upregulated (marker: CD45+) and that of tumor cells (marker: CD45−) was downregulated in CD45−GSDMEhigh group, which mean GSDME could enhance immunity against tumor (Supplementary Fig. 3e, f).